commonly known asred and blue cardOfTreatmentAfter Medicare began price negotiations on some of its most expensive prescription drugs under a new federal law, “U.S.” It was criticized by.SinopharmPharmaceutical industry groups such as Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit against the constitution, and Judge David A. Ezra issued a ruling on the 12th to dismiss the case. Newsweek reported and analyzed on the 13th that the judge’s decision is tantamount to a major victory for President Biden.
Ezra was a federal judge appointed by former President Ronald Reagan. The Pharmaceutical Association of America issued a statement saying it was disappointed by the decision.
Nicole Longo, a spokeswoman for the Pharmaceutical Manufacturers of America, told Reuters it was evaluating what further legal steps could be taken.
Prescription drugs with red and blue cards are open to price negotiations, and the Biden administration has several other similar lawsuits pending in court.
In 2022, Congress passed the “Inflation Reduction Act (IRA)”, authorizing the federal government to help red and blue card holders negotiate the price of prescription drugs for the first time. Producers who refuse to participate in price negotiations face heavy fines or are locked out of the red and blue card programs.
Big pharmaceutical companies and pharmaceutical industry organizations have challenged the new law. AstraZeneca (AZ), Astellas Pharma, Bristol Myers Squibb, Johnson & Johnson Pharmaceutical companies such as Johnson & Johnson and Merck have filed the lawsuit.
United States (TagstoTranslate) Red and Blue Cards (T) Sinopharm (T) Federal Medicare